Nanoparticle‐based immune checkpoint inhibitor therapy, including PD‐1 or PD‐L1 blockers, increases the local concentration of immune checkpoint inhibitors while reduces the side effects in anti‐tumor therapies.52 Here, PDCD1 is linked to neoplasm.